| Expression pattern: |
DN |
| Associated gene: |
KLF9 |
| Associated microRNA: |
miR-636 |
| Biological function: |
inhibits BC cell proliferation in vitro and tumor growth in vivo |
| Molecular mechanism: |
circPTPRA acts as a ceRNA by sponging miR-636 to relieve miR-636-mediated repression of KLF9 |
| Biological pathway or process: |
proliferation (inhibits); ceRNA regulation (other) |
| Detected method: |
Q
|
| Validation methods: |
Bioinformatics Analysis; RT-qPCR; Back-Splice Junction PCR / divergent primers PCR; Sanger Sequencing; Actinomycin D / DRB Stability Assay; RNase R Treatment; Nuclear-Cytoplasmic Fractionation; FISH / smFISH; RNA Pull-Down; Luciferase Reporter Assay; Transfection; CCK8; Colony Formation Assay; Western Blot; IHC (Immunohistochemistry); Clinical Sample Validation; Survival Analysis; In Vivo Animal Model |
| Clinical significance: |
low circPTPRA expression is associated with poor prognosis, advanced tumor stage and larger tumor size |
| Description: |
circPTPRA is down-regulated in bladder cancer and functions as a tumor suppressor. It mainly localizes in the cytoplasm and acts as a ceRNA that sponges miR-636, thereby relieving repression of KLF9 and inhibiting bladder cancer cell proliferation and xenograft tumor growth. Low circPTPRA expression is associated with poor prognosis and more advanced disease features. |
| Confidence score: |
0.8806 |